日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Targeting the USP7-CDK1 axis suppresses estrogen receptor-positive breast cancer progression

靶向 USP7-CDK1 轴可抑制雌激素受体阳性乳腺癌进展

Joseph Lin #, Yueh-Te Lin #, Kai-Wen Hsu #, Yi-En Liu, Yun-Cen Chen, Yung-Liang Yeh, Hsin-Ya Huang, Chang-Chi Hsieh, Dar-Ren Chen, Han-Tsang Wu1

Trop-2 expression in non-small cell lung cancer.

非小细胞肺癌中Trop-2的表达

Kuo Peiwen, Elboudwarej Emon, Zavodovskaya Marianna, Lin Kai-Wen, Lee Chingwei V, Diehl Lauri, Patel Jilpa, Mekan Sabeen, Jürgensmeier Juliane M

Efficacy and Safety of Sacituzumab Govitecan in Patients With Advanced Solid Tumors (TROPiCS-03): Analysis in Patients With Advanced Endometrial Cancer

Sacituzumab Govitecan治疗晚期实体瘤患者的疗效和安全性(TROPiCS-03):晚期子宫内膜癌患者的分析

Santin, Alessandro D; Corr, Bradley R; Spira, Alexander; Willmott, Lyndsay; Butrynski, James; Tse, Ka Yu; Patel, Jilpa; Mekan, Sabeen; Wu, Tia; Lin, Kai-Wen; Kuo, Peiwen; Dumbrava, Ecaterina E

Oral PD-L1 inhibitor GS-4224 selectively engages PD-L1 high cells and elicits pharmacodynamic responses in patients with advanced solid tumors

口服PD-L1抑制剂GS-4224选择性地与PD-L1高表达细胞结合,并在晚期实体瘤患者中引发药效学反应。

Odegard, Jared M; Othman, Ahmed A; Lin, Kai-Wen; Wang, Adele Y; Nazareno, Jonathan; Yoon, Oh Kyu; Ling, John; Lad, Latesh; Dunbar, P Rod; Thai, Dung; Ang, Edmond; Waldron, Nicholas; Deva, Sanjeev

Phase I Study of GS-3583, an FMS-like Tyrosine Kinase 3 Agonist Fc Fusion Protein, in Patients with Advanced Solid Tumors

GS-3583(一种FMS样酪氨酸激酶3激动剂Fc融合蛋白)在晚期实体瘤患者中的I期研究

Tolcher, Anthony W; Brody, Joshua D; Rajakumaraswamy, Nishanthan; Kuhne, Michelle; Trowe, Torsten; Dauki, Anees M; Pai, Shantheri; Han, Ling; Lin, Kai-Wen; Petrarca, Michael; Kummar, Shivaani

G-cleave LC3B biosensor: monitoring autophagy and assessing resveratrol's synergistic impact on doxorubicin-induced apoptosis in breast cancer cells

G-cleave LC3B 生物传感器:监测自噬并评估白藜芦醇对乳腺癌细胞阿霉素诱导的细胞凋亡的协同影响

Chiao-Chun Liao, Yuqing Long, Ming-Lin Tsai, Chun-Yu Lin, Kai-Wen Hsu, Chia-Hwa Lee3

Pharmacokinetics, pharmacodynamics, and safety of GS-3583, a FLT3 agonist Fc fusion protein, from single-ascending-dose phase I study in healthy participants

GS-3583(一种FLT3激动剂Fc融合蛋白)在健康受试者中单次递增剂量I期研究中的药代动力学、药效学和安全性

Dauki, Anees M; Rajakumaraswamy, Nishanthan; Trowe, Torsten; Weng, Winnie; Lin, Kai-Wen; Elboudjwarej, Emon; Qin, Ann Ran-Ran; Schwabe, Christian; Kuhne, Michelle R; Othman, Ahmed A

CRISPR-mediated knockout of VEGFR2/KDR inhibits cell growth in a squamous thyroid cancer cell line

CRISPR 介导的 VEGFR2/KDR 敲除可抑制鳞状甲状腺癌细胞系的细胞生长

Ming-Lin Tsai, Chia-Hwa Lee, Li-Chi Huang, Yu-Hsin Chen, Wei-Ni Liu, Chun-Yu Lin, Kai-Wen Hsu, Ai-Wei Lee, Ching-Ling Lin

Randomized, open-label, phase 2 study of andecaliximab plus nivolumab versus nivolumab alone in advanced gastric cancer identifies biomarkers associated with survival

一项随机、开放标签的 II 期研究比较了安德卡利昔单抗联合纳武利尤单抗与单用纳武利尤单抗治疗晚期胃癌的疗效,并确定了与生存相关的生物标志物。

Shah, Manish A; Cunningham, David; Metges, Jean-Philippe; Van Cutsem, Eric; Wainberg, Zev; Elboudwarej, Emon; Lin, Kai-Wen; Turner, Scott; Zavodovskaya, Marianna; Inzunza, David; Liu, Jinfeng; Patterson, Scott D; Zhou, Jingzhu; He, Jing; Thai, Dung; Bhargava, Pankaj; Brachmann, Carrie Baker; Cantenacci, Daniel V T

Embedded Immunodetection System for Fecal Occult Blood

用于粪便隐血的嵌入式免疫检测系统

Lin, Kai-Wen; Chang, Yu-Chi